ReviewChirurgie (Heidelberg, Germany)2026
[Primary and secondary microsurgical reconstruction in soft tissue sarcomas].
Review in Chirurgie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The reconstruction after soft tissue sarcoma resection is sometimes essential to enable radical R0 resection, limb salvage, satisfactory functional outcomes and timely adjuvant treatment. In a retrospective cohort of 76 soft tissue reconstructions of the lower limbs, predominantly following external resections, wound coverage was consistently performed in a staged manner with a mean interval of 18 days; in more than half of the cases this interval was ≤14 days. A comprehensive review of the scientific literature on soft tissue reconstruction after soft tissue sarcoma resection was conducted. Key prerequisites for maximum oncological safety and reconstructive reliability without delaying adjuvant therapy are plastic and reconstructive expertise within the sarcoma center, expedited pathological margin assessment and close collaboration with vascular surgery and radiotherapy.
Indexed as
Identifiers
42836954What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.